What Is the Recommended Dose of Semaglutide for Weight Loss?

You've been prescribed Wegovy. Here's what the dose schedule actually looks like

Picture the scenario: your prescription arrives, you open the box, and the pen says 0.25 mg. If you were expecting a medicine that produces 15% average weight loss, a quarter of a milligram probably feels underwhelming. That's a question our prescribers hear most weeks, and the answer is that the opening dose isn't doing the heavy lifting yet. It's conditioning your system to tolerate the medicine before the therapeutic doses begin.

The standard injection schedule runs: 0.25 mg for the first four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg as the maintenance dose, spending approximately four weeks at each rung, and our guide to how semaglutide dosing works explains the reasoning behind each step in full. At 2.4 mg, the STEP 1 trial (published in the New England Journal of Medicine) recorded an average body-weight reduction of around 15% over 68 weeks in adults with obesity. That figure is a trial average; individual outcomes vary.

A dedicated guide to all Wegovy dose strengths covers what each stage involves in more detail. For now, the practical point is this: the titration ladder is not negotiable on a whim. Jumping from 0.5 mg to 2.4 mg in a single step is not how the medicine is designed to be used, and a prescriber will not approve it without clinical reason. Patience with the schedule pays off in tolerability.

The 7.2 mg option, who it's for and what changed in 2026

For some people, 2.4 mg remains the ceiling. For others, there's now a higher step. The MHRA approved a 7.2 mg maintenance dose for semaglutide in January 2026 and, on 14 April 2026, confirmed a dedicated single-dose 7.2 mg pen, one pre-set weekly injection, built-in covered needle, locking mechanism after use. Early trial data suggested average weight loss of around 20.7% over 72 weeks at this dose, narrowing the gap with the results seen from tirzepatide at its highest strength.

The 7.2 mg pen carries an important restriction: it is licensed for adults with a BMI of 30 or above only. It is not approved for the lower BMI threshold that applies to people with weight-related health conditions, and it is not approved for the cardiovascular-risk indication. Starting dose still begins at 0.25 mg; if you want to understand what reaching the semaglutide 2 mg dose milestone looks like before progressing further, that page walks through what patients typically experience at that stage. You can read more about Wegovy's UK licence and what the approved pen formats mean for patients.

Whether a specific pen format is in stock at any given time is confirmed during consultation, no reputable clinic should promise a particular dose or device before reviewing your clinical picture. That's worth keeping in mind when comparing services.

Oral semaglutide: a different dose scale entirely

The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, uses a completely separate dose scale. The daily tablet schedule runs 1.5 mg → 4 mg → 9 mg → 25 mg, spending at least one month at each level. These figures are not comparable to the injection doses, the oral form uses a different absorption mechanism (co-formulated with the enhancer SNAC), so the numbers don't translate directly.

One practical detail that catches people out: the tablet must be taken first thing in the morning, on an empty stomach, with a small amount of plain water (up to about 120 ml), and you should wait at least 30 minutes before any food, drink (including coffee) or other oral medicines. Setting it next to your phone charger rather than beside the kettle helps, because the kettle is usually the problem. The NHS medicines page for semaglutide outlines storage and general use guidance for both forms.

People who are already established on the 2.4 mg weekly injection may be able to transition directly to the 25 mg tablet, but this requires a prescriber's assessment, it's not automatic. Anyone considering that switch should raise it during their next clinical review rather than making the change independently, and our page covering what 5 mg of semaglutide means in the context of oral dosing helps clarify where that intermediate step sits in the tablet titration pathway. The oral route is also covered on our weight-loss treatment overview, including how the two forms compare practically for everyday use.

What the recommended dose doesn't tell you, and when to get help

The licensed dose schedule tells you the framework; it can't tell you how your body will respond at each stage. Some people find the jump to 1.7 mg or 2.4 mg brings a return of nausea that had settled down. Others tolerate each increase without much difficulty. Adjusting the pace (pausing at a particular dose for longer) is something a prescriber can do, and it's a legitimate clinical decision, not a failure. What a prescriber cannot do is prescribe a dose that falls outside the licensed schedule without a specific clinical rationale.

A few symptoms should prompt urgent medical attention regardless of which dose you're on: severe stomach pain that radiates to the back (which can indicate pancreatitis), signs of a serious allergic reaction, or persistent vomiting that's preventing you from keeping fluids down. The MHRA Yellow Card scheme lets patients report suspected side effects directly, something worth bookmarking.

If you're weighing up the cost of ongoing treatment alongside the clinical side, the Wegovy price comparison page gives an honest breakdown of what private prescriptions typically include and where headline figures can mislead. And if you'd like a prescriber to review whether semaglutide is suitable for you, a free consultation is the starting point, no commitment before that clinical picture is clear.

Check your eligibility by starting a free consultation with our prescribers, reviewed the same day by a real clinician, not software.